Study Links Persistent Tumor Mutation with Therapeutic Response to Immunotherapy Schedule
Investigators have found that a subset of mutations within the overall tumor mutation burden are less likely to be edited out as cancer evolves.
Post-AMI Infusion of Human Apolipoprotein A-1 (CSL112) Strongly Boosts Impaired Cholesterol Efflux Capacity
Infusion of CSL112, an investigational human plasma-derived apolipoprotein A-1 formulated with phosphatidylcholine, rapidly and strongly elevates impaired cholesterol efflux capacity following acute myocardial infarction.
IVIG May Improve Survival in Patients with Acute Exacerbation of Fibrotic Idiopathic Interstitial Pneumonia
Investigators have found that intravenous immune globulin may have a positive effect on acute exacerbation of fibrotic idiopathic interstitial pneumonias.
Alpha-1 Antitrypsin Deficiency: A Wealth of New Treatments Now in Clinical Testing
The shortcomings of AAT augmentation therapy for AATD are currently the targets of a diverse range of new investigational therapies.
Update on Treatment Options for Alzheimer’s
While a cure for Alzheimer’s remains elusive, new diagnostic tools and treatment options are improving patient quality of life.
Breakthroughs in Gene Therapy
Exciting new developments in gene therapy and genome editing show promise for treating a variety of genetic diseases.
Fitusiran Prophylaxis Reduces Bleeds Versus Prior Factor or Bypassing Agent Prophylaxis in Hemophilia A and B Patients
Sanofi’s fitusiran significantly reduced bleeding in a Phase III multinational study in adults and adolescents with hemophilia A or B, with or without inhibitors.
Novel Immunotherapies Target RSV Disease at Both Ends of the Age Spectrum
RSV infections account for a large share of U.S. hospitalizations for lower respiratory tract disease due in large part to a lack of immunization and prophylactic therapies, but new developments and cutting-edge therapies may soon become standard medical practice.
High-Dose IVIG Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments
Italian investigators conducted a trial to assess the safety and efficacy of IVIG in treatment-resistant painful diabetic polyneuropathy (DPN).
Neonatal Fc Receptor Blockers for Myasthenia Gravis: The Concept Is Now Reality
While acetylcholinesterase inhibitors, corticosteroids and thymectomy are generally considered first-line therapies for MG, many patients additionally require proven immunosuppressive therapies (ISTs) such as azathioprine, cyclosporine/tacrolimus or mycophenolate mofetil, or immunomodulatory therapies, including intravenous immune globulin (IVIG) or plasma exchange (PLEX).
